Novel Hsp90-Targeting PROTACs: Enhanced synergy with cisplatin in combination therapy of cervical cancer

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Cervical cancer has a high mortality rate with limited treatment options.
• Heat Shock Protein 90 (Hsp90) is a crucial target in cancer therapy.
• Novel therapeutic strategies are urgently needed for effective cervical cancer treatment.

Purpose of the Study:

• To design, synthesize, and evaluate novel Hsp90-targeting Proteolysis Targeting Chimeras (PROTACs) for cervical cancer.
• To assess the anti-proliferative, anti-metastatic, and cell cycle effects of these compounds.
• To investigate the in vitro and in vivo antitumor efficacy and synergistic potential with existing therapies.

Main Methods:

• Synthesis and chemical characterization of novel Hsp90-targeting PROTACs.
• In vitro evaluation of anti-proliferative activity (IC50 values) and Hsp90 degradation.
• Assessment of effects on cancer cell metastasis, cell cycle progression, and apoptosis.
• In vivo antitumor studies and combination therapy with cisplatin.
• Analysis of signaling pathway modulation (HER2/AKT/mTOR).

Main Results:

• Novel PROTACs demonstrated potent anti-proliferative activity against cervical cancer cells.
• Compound lw13 effectively degraded Hsp90 at low concentrations (0.05 μM).
• lw13 inhibited cancer cell metastasis, induced cell cycle arrest and apoptosis, and showed significant antitumor activity in vitro and in vivo.
• lw13 exhibited a synergistic effect with cisplatin and inhibited the HER2/AKT/mTOR pathway.

Conclusions:

• Novel Hsp90-targeting PROTACs, particularly lw13, are effective against cervical cancer.
• lw13 demonstrates broad anti-cancer effects including Hsp90 degradation, anti-metastasis, and apoptosis induction.
• This study provides a promising new therapeutic agent for cervical cancer and insights into combination therapy.